AOD 9604
Also known as: HGH Fragment 176-191 modificado
Molecular Identifiers
Overview
Modified HGH fragment (amino acids 176-191) that acts on fat metabolism without affecting blood glucose or insulin levels. Promotes lipolysis and inhibits lipogenesis.
YLRIVQCRSVEGSCGF Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Half-life
~30 minutes
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- Stimulation of lipolysis via beta-3 adrenergic receptor
- Inhibition of lipogenesis
- No effect on blood glucose or IGF-1
- Mimics the lipolytic action of GH without anabolic effects
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 300-600 mcg per injection |
| Frequency | Once daily |
| Timing | Morning, fasted |
| Duration | 12+ weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Mild headache
- Local redness
Presentations & Preparation
Vials of AOD 9604 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per 5 mg vial
- Slowly inject the diluent along the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on AOD 9604.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)